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RNase L contributes to
experimentally induced type 1
diabetes onset in mice
Chun Zeng , Xin Y , Danny Zipris , Hongli Liu , Lin Zhang , Qiaoyun Zheng ,
Krishnamurthy Malath , Ge Jin and Aimin Zhou
Abstract
The cause of type 1 diabetes continues to be a focus of investigation. Studies have revealed that
interferon a (IFNa) in pancreatic islets after viral infection or treatment with double-stranded
RNA (dsRNA),a mimicofviral infection, is associated with the onset of type 1 diabetes. However,
how IFNa contributes to the onset of type 1 diabetes is obscure. In this study, we found that
2-5A-dependent RNase L (RNase L), an IFNa-inducible enzyme that functions in the antiviral and
antiproliferative activities of IFN, played an important role in dsRNA-induced onset of type 1
diabetes. Using RNase L-deficient, rat insulin promoter-B7.1 transgenic mice, which are more
vulnerable to harmful environmental factors such as viral infection, we demonstrated that
deficiency of RNase L in mice resulted in a significant delay of diabetes onset induced by
polyinosinic:polycytidylic acid (poly I:C), a type of synthetic dsRNA, and streptozotocin, a drug
which can artificially induce type 1-like diabetes in experimental animals. Immunohisto-
chemical staining results indicated that the population of infiltrated CD8CT cells was
remarkably reduced in the islets of RNase L-deficient mice, indicating that RNase L may
contribute to type 1 diabetes onset through regulating immune responses. Furthermore, RNase
L was responsible for the expression of certain proinflammatory genes in the pancreas under
induced conditions. Our findings provide new insights into the molecular mechanism
underlying b-cell destruction and may indicate novel therapeutic strategies for treatment
and prevention of the disease based on the selective regulation and inhibition of RNase L.
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Introduction
The etiology of diabetes continues to be a focus of
investigation. Both genetic and environmental factors
such as toxins, viruses, and diets are believed to play
an important role in its pathogenesis (Mathis et al. 2001).
A reduction in insulin-producing pancreatic b-cells has
been considered to be one of the key factors in the
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development of diabetes, particularly type 1 diabetes (Yoon
& Jun 2001, Mandrup-Poulsen 2003). In type 1 diabetes,
autoimmune destruction of the pancreatic b-cells results in
an absolute loss of insulin production. Investigation of the
molecular mechanisms underlying b-cell destruction has
revealed that microbial infection recruits immune effectors
mediating b-cell apoptosis, which in turn triggers auto-
immuneresponses (Anderson&Bluestone2005).NODmice
are an ideal model of spontaneous type 1 diabetes, a T-cell-
mediated autoimmune disease. Results from histological
studies have indicated that infiltration of immune cells,
including macrophages and lymphocytes, around the islets
in NOD mice starts at 3 4 weeks of age, causing insulitis
(Solomon & Sarvetnick 2004, Anderson & Bluestone 2005).
It has been well demonstrated that CD4C and CD8CT cells
play an important role in the onset of type 1 diabetes.
Results from clinical and animal studies have demonstrated
that CD8CT cells take a central stage in the destruction of
pancreatic b-cells and contribute to sustaining islet
inflammation, leading to the onset of type 1 diabetes
(Solomon & Sarvetnick 2004, Anderson & Bluestone 2005,
Coppieters & von Herrath 2011, Coppieters et al. 2012).
The expression of proinflammatory genes has been
implicated in the pathogenesis of type 1 diabetes
(Bergholdt et al. 2004). In NODmice, increased expression
of IFNg, TNFa, and IL1b is associated with b-cell-
destructive insulitis (Solomon & Sarvetnick 2004,
Anderson & Bluestone 2005). In recent years, the role of
IFNa in autoimmune diseases including type 1 diabetes
has been well established (Selmi et al. 2006). Increased
levels of IFNa in the sera of type 1 diabetic patients have
been documented (Chehadeh et al. 2000). Transgenicmice
expressing IFNa (IFNA) in the b-cells develop hypoinsuli-
nemic diabetes associated with a mixed inflammation
centered on the islet, which can be prevented with a
neutralizing antibody to IFNa (Stewart et al. 1993). It has
been reported that the onset of type 1 diabetes in both
BB rats and streptozotocin (STZ)-treated mice is IFNa-
dependent (Huang et al. 1994). In addition, IFNamediates
induction of type 1 diabetes by poly I:C inmice expressing
the B7.1 costimulatory molecule driven by the rat insulin
promoter (RIP) on b-cells in islets (Devendra et al. 2005).
Most recently, a study has revealed that blockade of IFNa
signaling by anti-IFNAR1 in 2- to 3-week-old NOD mice
remarkably delays the onset and decreases the incidence
of diabetes, indicating the involvement of IFN-stimulated
genes in the pathogenesis of type 1 diabetes (Li et al. 2008).
RNase L is an IFN-inducible enzyme and plays an
important role in the 2-5A system of IFN action against
viral infection and cellular proliferation (Silverman 1996).
The 2-5A system consists of two enzymes: 2-5A synthetase
and RNase L. IFNs induce a family of 2-5A synthetase genes.
The 2-5A synthetases require double-stranded RNA (dsRNA)
for their activities. dsRNA is frequently produced during
viral infection. After activation by dsRNA, 2-5A synthetases
convert ATP molecules to pyrophosphate (ppi) and a series
of unique, 50-phosphorylated, 20-50 linked oligoadenylates
known as 2-5A with the general formula ppp(A20p50)nA
(nR2). 2-5A binds RNase L with a high affinity, converting
it from its inactive, monomeric state to a potent dimeric
endoribonuclease, resulting in degradation of single-
stranded viral and cellular RNAs (Zhou et al. 1993). It has
been demonstrated that 2-5A accumulates and RNase L is
activated in infected cells. Cells overexpressing RNase L
overcome viral infection (Zhou, et al. 1998). In contrast,
overexpression of a dominant negative mutant of RNase L
results in increased susceptibility to certain viruses
(Hassel et al. 1993). Results from in vivo studies indicated
that mice containing targeted disruption of RNase L
gene succumb to encephalomyocarditis (EMCV) infection
more rapidly than infected WT mice (Zhou et al. 1997).
Interestingly, 2-5A synthetase is persistently activated in
patients with type 1 diabetes, indicating its involvement
in this disease (Bonnevie-Nielsen et al. 2000). RNase L-null
mice show enlarged thymus glands and increased T cell
numbers at an early age, indicating that RNase L may be
involved in T cell development, which probably results
from reduced cell apoptosis. Furthermore, it has been
demonstrated that overexpression of RNase L in the cells
enhances cell apoptosis, whereas dominant negative
RNase L suppresses cell apoptosis (Zhou et al. 1997). These
observations indicate that RNase L plays an important role
in the immune system. Indeed, studies have revealed that
skin allograft rejection is suppressed in mice lacking
RNase L, indicating the involvement of RNase L in T cell
immunity, particularly CD4CT cell-mediated immunity
(Silverman et al. 2002). In addition, alphavirus-based DNA
vaccination against a non-mutated tumor-associated self-
antigen (tyrosinase-related protein-1, TRP-1) is severely
impaired in RNase L-null mice, indicating that RNase L
plays an important role in the host’s immune response
against cancer (Leitner et al. 2003).
In this study, we present evidence indicating that
RNase L may be involved in the pathogenesis of type 1
diabetes. RNase L-deficient RIP-B7.1 mice displayed
significantly delayed onset of diabetes induced by STZ
and poly I:C. Immunohistostaining revealed that the
population of infiltrated CD8CT cells was remarkably
reduced in the islets of RNase L-deficient mice, implicating
RNase L in the onset of type 1 diabetes through mediating
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the infiltration of immune cells. Furthermore, RNase L
regulated the expression of certain proinflammatory
genes in the pancreas under these conditions. Our
results are indicative of a novel role of RNase L in the
development of type 1 diabetes.
Reagents and methods
Tissue culture and animal treatment
NIH 3T3 cells, NIT-1 (ATCC, Manassas, VA, USA), and
mouse embryonic fibroblasts (MEFs) were grown in DMEM
(ClevelandClinic, Cleveland, OH,USA) supplementedwith
10% fetal bovine serum (PAA Laboratories, Dartmouth,
MA, USA) and antibiotics in a humidified atmosphere of 5%
CO2 at 37 8C. BMMs were generated from the bone marrow
cells of RNase L-deficient and WT C57BL/6 mice using a
modified method (Yi et al. 2013). For RNase L induction in
the pancreas of mice, each group (nZ2) of C57BJ/6 mice
were treated with or without poly I:C at a concentration of
5 mg/g body weight every other days for 1 week (three
times). The pancreases were removed and tissue extracts
were used for analysis of RNase L. For treatment with a
high-fat diet, RNase LC/C and RNase L / mice were fed a
high-fat diet (21% milk fat, 1.25% cholesterol, and 0.5%
sodium cholate) (Harlan Teklad, Madison, WI, USA) for
20 weeks. The body weight was monitored every 2 weeks
and the blood from the eye corner was collected for analysis
of glucose, cholesterol, triglyceride, and insulin. This study
was carried out in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol
was approved by the Committee on the Ethics of Animal
Experiments of Cleveland State University (Permit Number:
21111-ZHO-AS). All efforts were made to reduce suffering.
Mice were anaesthetized under CO2 for 5 min and then
their necks were dislocated at the end of the experiments.
Generation of an RNase L-deficient C57BL/6.RIP-B7.1
mouse
An RNase L / mouse (C57BL/6) (a generous gift from
Dr Robert Silverman, Cleveland Clinic) was cross-bred
with a C57BL/6.RIP-B7.1 mouse (Barbara Davis Center of
Childhood Diabetes, University of Colorado Health
Sciences Center, Denver, CO, USA). Genotyping for
RNase L and B7.1 was performed by PCR under the
following conditions: denaturation at 96 8C for 4 min, for
each cycle, denaturation at 96 8C for 45 s, annealing at
55 8C for 45 s, and extension at 72 8C for 1.5 min, for
32 cycles, then an additional cycle at 72 8C for 5 min.
The primers used were as follows: RNase L, 5 0-GCA TTG
AGG ACC ATG GAG AC-3 0 and 5 0-GGA GGA GAA GCT
TTA CAA GGT-3 0 and, B7.1, 5 0-TGA AGC CAT GGG CCA
CAC-3 0 and 5 0-GGC TCC TTG TCG GCG TTC TA-3 0.
Diabetes induction
Six-week-old RNase L-deficient and WT C57BL/6 RIP-B7.1
mice received i.p. injections of with poly I:C (Sigma) daily
at a concentration of 5 mg/g body weight for 7 days, and
then immunized (i.p.) with 25 mg/mouse insulin (Eli Lilly,
Indianapolis, IN, USA) on day 14 after poly I:C treatment.
Blood glucose was measured weekly using a Glucose
Oxidase Reagent Set (Pointe Scientific, Canton, MI, USA).
Briefly, 10 ml of plasma was mixed with 1 ml of the
working reagent provided by the manufacturer and
incubated at 37 8C for exactly 5 min. After incubation,
the absorbance at 500 nm was read and recorded. Mice
were considered diabetic after two consecutive blood
glucose values of at least 250 mg/dl.
Immunohistostaining
The pancreases obtained from mice were fixed in 10%
formalin, paraffin embedded, sectioned at a thickness
of 5 mm, and subsequently stained with hematoxylin and
eosin. Pancreatic sections were microscopically examined
for infiltration of immune cells. The tissue sections were
incubated with rat polyclonal antibodies against CD4, CD8,
F4/80, and CD11b (eBioscience, San Diego, CA, USA)
respectively and a MAB to insulin (Abcam, Cambridge, MA,
USA), followed by incubation with a biotinylated secondary
antibody, and color reaction was obtained by sequential
incubation with avidin-peroxidase conjugate and diamino-
benzidine-hydrogen peroxide (ICN, Costa Mesa, CA, USA).
Flow cytometry
Single-cell suspensions from the spleens were stained
with conjugated mAbs including FITC-CD4, PE-CD8,
FITC-IgD, PE-B220, and PE-cy7-CD25 (BD Pharmingen,
San Jose, CA, USA). Cell-associated fluorescence was
analyzed with a FACScan instrument and the associated
Winlist 5 software.
Western blot analysis
After treatment, cells were washed twice with ice-cold
PBS and collected with a scraper. Western blot analysis
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RNase L facilitates infiltration of immune cells
RNase L is highly expressed in the thymus, spleen, and all
immune cells examined. As the infiltration of immune
cells initiates the progress of this disease, we investigated
whether the delay in the onset of type 1 diabetes was
caused by slowdown of immune responses in the
pancreases of RNase L-deficient mice. RNase LC/C and
RNase L / RIP-B7.1 mice were treated with poly I:C for
40 days and then killed and the pancreatic tissues were
embedded and sectioned at a thickness of 5 mm, followed
by hematoxylin and eosin (H&E) staining. Interestingly,
the population of infiltrated immune cells was strikingly
reduced in the islets of RNase L / mice, indicating that
the involvement of RNase L in poly I:C-induced onset of
diabetes may be through the regulation of the infiltration
of immune cells (Fig. 4A). To determine the identity of
these infiltrated immune cells, immunohistostaining
for macrophages, CD4C, and CD8CT cells was performed.
Apparently, the majority of the infiltrated immune cells
in the islets of the pancreas from RNase LC/C mice were
CD8-positive T cells, although some CD4-positive T cells
were found in islets from both types of mice (Fig. 4B).
However, macrophages were undetectable in the islets
from both types of mice using either CD11b or F4/80
as a biomarker (not shown). The finding indicates that
CD8-positive T cells may be the effector cells in the
destruction of b-cells in the islets of the pancreas from
RNase LC/C RIP-B7.1 mice after poly I:C treatment. As
expected, the insulin levels in the islets of RNase L /
mice were significantly higher than those in RNase LC/C
mice before and after poly I:C treatment (Fig. 4C).
RNase L is associated with subclasses of immune cells
in the spleen and T cell function in the blood
RNase L / mice display enlarged, hypercellular
thymuses, indicating that RNase L may be involved
in the development of thymocytes and T cell function.
To determine whether RNase L affects T cell function,
lymphocytes isolated from the blood of RNase LC/C and
RNase L / mice were subjected to analysis of their
cytotoxic activity against retinal endothelial cells. As
shown in Fig. 5A, lymphocytes from RNase L / mice
exerted 46% lower cytotoxic activity than those from
RNase LC/C mice. CD4CCD25C regulatory T cells (Tregs)
have emerged as a dominant peripheral mechanism
of immune suppression of self-reactive T cells and a
master switch factor controlling the balance between
tolerance and immunity (Johnson et al. 2013). It has
been demonstrated that CD4CCD25C Tregs, in par-
ticular CD4CCD25CFoxP3C Tregs, are very important
in controlling the development of diabetes in NOD
mice (Manirarora et al. 2008, Kaminitz et al. 2014).
RNase L+/+A
B
C
RNase L–/–
RNase L+/+ RNase L–/–
RNase L+/+
CD8+
Poly I:C
Control
Poly I:C
Control
CD4+
RNase L–/–
Figure 4
RNase L dependent infiltration of immune cells in the islets in response
to poly I:C. (A) Hematoxylin and eosin stained pancreatic islets from
B7.1 RLC/C and B7.1 RLK/Kmice after treatment with or without poly I:C.
(B) Immunohistological staining of CD4C and CD8CT cells in the islets from
the two types of mice after poly I:C treatment. (C) Immunohistological
staining of insulin in the islets from the two types of mice before and after
poly I:C treatment. Magnification !40.
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To determine the effect of RNase L on CD4CCD25C
Tregs, we performed a flow cytometric assay to analyze
the subtype of these cells in the spleen of RNase LC/C and
RNase L / mice. Interestingly, the percentage of
CD4CCD25C Tregs in CD4CT cells in the spleens of
RNase L / mice was significantly higher than that in
those of RNase LC/C mice. In particular the percentage
of CD4CCD25CfoxP3C Tregs in CD4CT cells was 13.3%
in the spleens of RNase L / mice when compared with
5.2% in the spleens of RNase LC/C mice (Fig. 5B and C).
The population of other cell subclasses was also differen-
tially represented in the spleens of RNase LC/C and RNase
L / mice, especially under stimulation with LPS as
shown in Fig. 5D and E. The population of CD4CCD8CT
cells in the spleens of RNase L / mice was 37% less than
that in the spleens of RNase LC/C mice, whereas the
population of the double-labeled T cells was 72% less in
the spleens of RNase L / mice when compared with that
in the spleens of RNase LC/C mice after treatment with
LPS. Similar to CD4CCD8CT cells, the population of
B220CIgDCB cells in the spleens of RNase L / mice was
39% less than that in the spleens of RNase LC/C mice
after LPS stimulation, although the population of
B220CIgDCB cells in the spleens of intact RNase L /
mice was slightly higher than that in the spleens of RNase
LC/C mice under the same conditions. Taken together,
the results implicate RNase L in immune system activities
through mediating the context-specific modulation of
immune cell subclasses in the spleen.
The expression of proinflammatory cytokines
in the pancreatic tissues
In addition to IFNa, several proinflammatory genes such
as TNFa, IL1b, and IFNg are believed to contribute to the
development of type 1 diabetes (Solomon & Sarvetnick
2004, Anderson & Bluestone 2005). To determine
whether deficiency of RNase L affects the expression of
TNFa, IL1b, IL6, and IFNg, RNase LC/C and RNase
L / RIP-B7.1 mice were treated with poly I:C at a
concentration of 5 mg/g body weight every other day for
a week and the level of these gene products in the
pancreatic extracts was determined by ELISA. As shown
in Fig. 6, RNase L deficiency reduced IFNg and TNFa
production by 37.5 and 48.5%, respectively, in the
pancreas after treatment with poly I:C. However, the
expression of IL1b and IL6 was found to be slightly higher
in the pancreases from RNase LC/C mice when compared
with the pancreases from RNase-L / mice.
Discussion
B7.1 and B7.2 are homologous costimulatory ligands
expressed on the surface of antigen-presenting cells
(APCs). Binding of these molecules to the T cell costimu-
latory receptors, CD28 and CTLA-4, is essential for the
activation and regulation of T cell immunity (Greenwald
et al. 2005). Although expression of the B7.1 costimulator
alone is not sufficient to induce diabetes in mice, b-cells
expressing the molecule are more vulnerable to harmful
environmental factors such as viral infection, resulting in
the destructionof b-cells and leading to disease (Wong et al.
1995). As a mimic of viral infection, poly I:C treatment
alone can induce insulitis, but cannot lead to diabetes
in C57BL/6 mice. However, it can effectively induce
diabetes in C57BL/6 mice expressing B7.1 on b-cells in
the islets under the control of a RIP (Devendra et al. 2005).
In this study, we present evidence indicating that RNase
L / RIP-B7.1 mice display a significant delay of type 1
diabetes onset induced by poly I:C, indicating that
RNase L is associated with the pathogenesis of this disease.
The role of RNase L in mediating IFN-induced actions
against viral infection and cell proliferation has been well
established. A line of evidence has shown that IFNa plays
a vital role in initiating autoimmune responses and the
molecular mechanism is a continuing subject of investi-
gation. Studies have revealed that the onset of type 1
diabetes in animal models induced by STZ and poly I:C is
IFNa-dependent (Huang et al. 1994, Devendra et al. 2005).
In humans, the development of type 1 diabetes has been
widely documented during IFNa therapy for viral infections
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Figure 6
RNase L regulates the expression of proinflammatory genes. RNase
L deficient and WT RIP B7.1 mice were treated with poly I:C at a
concentration of 5 mg/g body weight every other day for a week and the
level of these factors in the pancreatic extracts was determined by ELISA
using an ELISA kit for each of the analyzers. Experiments were carried out
two times in triplicates. Data are expressed as meanGS.D., P!0.01.
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such as hepatitis B and C (di Cesare et al. 1996, Kose et al.
2012). How IFNa promotes the onset of type 1 diabetes
remains to be further elucidated. RNase L is one of the key
enzymes in the 2-5A system of IFNa function. 2-5A
activation of RNase L results in apoptosis in cells. It is
believed that apoptosis is one of the key factors in triggering
autoimmune responses in islets (Kawazoe et al. 2012). Thus,
our results indicate that poly I:C treatment may induce
an increase in IFNa production in islets and subsequently
activate the 2-5A system. Activation of the 2-5A system,
in turn, leads to b-cell apoptosis, which further promotes the
autoimmuneresponses resulting indestructionofb-cells and
diabetesonset.DeficiencyofRNaseL inmicedelays theonset
of type 1 diabetes. Actually, this hypothesis is supported by
a previous study in which poly I:C induces cell apoptosis in
pancreatic islets, resulting in the releaseof islet autoantigens,
triggering the autoimmune responses. By contrast, none
of the bacterial products such as LPS and CpG are able to
induce diabetes in these mice because they cannot induce
islet cells to undergo overt apoptosis (Maniati et al. 2008).
RNase L may be involved directly in the action of
immune cells to affect the development of type 1 diabetes.
Although T lymphocytes are primarily the effectors, results
from previous studies have indicated that B cells may play
a vital role in the pathogenesis of autoimmune diseases.
In NOD mice, the contribution of B cells was clearly
demonstrated by the remarkable reduction in the incidence
of insulitis and diabetes after B cell depletion using anti-IgM
antibodies at birth or in NOD mice genetically deficient in
B cells (Silveira & Grey 2006, Marin˜o et al. 2011). Using the
same animal model, it has been demonstrated that B cells
function as islet antigen-presenting cells for autoreactive
T cells and produce antibodies that are directly pathogenic.
In clinical trials, patients with type 1 diabetes treated with
rituximab, a chimeric MAB against the protein CD20 that
is primarily found on the surface of B cells, decreased
C-peptide and reduced insulin requirements, indicating
an essential role of B cells in the development of
this disease (Pescovitz et al. 2009). Interestingly, the
populations of B220CIgDC double-labeled B cells and
CD4C/CD8C double-labeled T cells were 39% and 72%
down after LPS treatment (Fig. 2A) or 46% and 45% down
after poly I:C treatment (data not shown) in the spleens of
RNase L / mice, indicating that delayed onset of type 1
diabetes may be due to attenuated immune responses as a
resultofdecreases in thepopulationofcertain immunecells,
such as B cells, induced by LPS or poly I:C. The effect of
RNaseLonimmunity is a focusofour current investigations.
The production of proinflammatory genes in the islets
plays a critical role in the pathogenesis of type 1 diabetes.
It has been demonstrated that disruption of IFNg function
using either IFNg-specific Abs or soluble IFNg receptors
(IFNgR) significantly reduces the incidence of spontaneous
diabetes in NODmice, indicating an important role of IFNg
in the development of this disease (Campbell et al. 1991,
Nicoletti et al. 1996). Complete protection from diabetes
was observed when Tnfr1, but not Tnfr2 was knocked out
in NOD mice although the direct effect of TNFR1 on b-cell
death in vivo has not been defined clearly (Ka¨gi et al. 1999).
It has been reported that RNase L mediates the expression
of certain genes through regulating RNA turnover (Bisbal
et al. 2000, Chandrasekaran et al. 2004). Our results indicate
that RNase L specifically regulating the expression of
proinflammatory genes in the pancreas may contribute
to the onset of type 1 diabetes induced by poly I:C.
Interestingly, RNase L seemed not to influence the growth
rate of mice fed a high-fat diet, but the level of blood
glucose in RNase L / mice was significantly higher
although the insulin level was markedly increased, indica-
ting that insulin sensitivity in RNase L / cells may be
impaired. Indeed, we have observed that phosphorylation
of Akt, a key component of the insulin signaling pathway,
in RNase L / MEFs and primary hepatocytes stimulated
by insulin was significantly reduced when compared with
that in the same type of RNase LC/C cells (L Zhang and
A Zhou unpublished observations). Thus, this study high-
lights the potential benefits of targeting RNase L in
treatment of type 1 diabetes.
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